Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 27Breast Neoplasms 23Neoplasm Metastasis 14Glioma 14Carcinoma, Non-Small-Cell Lung 14Lymphoma 12Lung Neoplasms 11Glioblastoma 11Neuroblastoma 10Lymphoma, Non-Hodgkin 9Carcinoma, Renal Cell 9Brain Neoplasms 9Medulloblastoma 8Ovarian Neoplasms 7Neoplasms 7Multiple Myeloma 7Ependymoma 7Carcinoma, Hepatocellular 7Wilms Tumor 6Thyroid Neoplasms 6Sarcoma 6Rectal Neoplasms 6Pancreatic Neoplasms 6Osteosarcoma 6Melanoma 6Fallopian Tube Neoplasms 6Central Nervous System Neoplasms 6Uterine Cervical Neoplasms 5Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5

Interventions

pembrolizumab 1Magnetic Resonance Spectroscopy 1Ferrosoferric Oxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lung Carcinoma Metastatic in the Brain × Magnetic Resonance Spectroscopy × Clear all
NCT03325166 2022-08-10

Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases

OHSU Knight Cancer Institute

Phase 2 Terminated
2 enrolled 8 charts

Lung Carcinoma Metastatic in the Brain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡